Head honcho

Houston biopharmaceutical company brings on new CEO to grow company

A Houston biotech company has a new CEO and is ready for growth. Getty Images

With a veteran of the biopharmaceutical industry now aboard as its CEO and an executive at pharmaceutical giant AstraZeneca now serving on its board, Houston-based biopharmaceutical company Pulmotect Inc. is poised for progress.

In September, Dr. Colin Broom joined Pulmotect as CEO. He previously was CEO of Ireland-based Nabriva Therapeutics plc, a biopharmaceutical company that went public in 2015. During Broom's tenure at Nabriva, he helped develop the recently approved drug Xenleta, which treats bacterial pneumonia. Before that, he was chief scientific officer at Pennsylvania-based pharmaceutical company ViroPharma Inc., which Massachusetts-based Shire plc purchased for $4.2 billion in 2014.

Broom's hiring came on the heels of Kumar Srinivasan being named to Pulmotect's board of directors. Srinivasan is vice president of United Kingdom-based AstraZeneca and is its global head of business development and licensing for biopharmaceuticals R&D.

Researchers at MD Anderson Cancer Center and Texas A&M University invented Pulmotect's main product, PUL-042, which holds patents in nine countries. Pulmotect, founded in 2007, emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector.

"Attracting such a highly regarded and proven CEO as Colin is a clear signal of the power and potential of Pulmotect's development program," Pulmotect's executive chairman, Leo Linbeck III, founder and chairman of Fannin, says in a release. "Under his leadership, I'm confident that we will advance our technology further into the clinic and closer to the marketplace. His addition is a real game-changer for the company."

Both Broom and Srinivasan are focusing on clinical trials for Pulmotect's PUL-042 product, an inhaled therapy that holds the potential to prevent or treat respiratory infections caused by bacteria, viruses, or fungi. The current Phase 2 trial is evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus. The current trial is supposed to be followed by additional Phase 2 trials.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by preventing complications and hospitalizations, which typically result from COPD problems triggered by a bacterial or viral infection. PUL-042 could substantially decrease those complications, the company says.

Pulmotect seeks to gear PUL-042 toward patients with cancer who are undergoing chemotherapy, as their weakened immunity makes them highly susceptible to pneumonia, Broom says. If the product proves effective with those patients, then people at risk of developing respiratory infections also might benefit from it, including COPD patients and flu patients, he says.

To date, Pulmotect has raised more than $28 million in funding. That includes about $18 million in research grants, including a $7 million grant from the Cancer Prevention and Research Institute of Texas, as well as seven grants from the Small Business Innovation Research program.

Two of Pulmotect's three full-time employees work in Houston, and a team of consultants supports their work, Broom says. A small number of employees might be added during the current Phase 2 trial. Hiring would need to be ramped up if the Phase 2 trial demonstrates that PUL-042 works, he says.

Trending News

Building Houston

 
 

According to a new report, Houston's workforce isn't among the happiest in the nation. Photo via Getty Images

Call it the Bayou City Blues. A report from job website Lensa ranks Houston third among the U.S. cities with the unhappiest workers.

The report looks at four factors — vacation days taken, hours worked per week, average pay, and overall happiness — to determine the happiest and unhappiest cities for U.S. workers.

Lensa examined data for 30 major cities, including Dallas and San Antonio. Dallas appears at the top of the list of the cities with the unhappiest workers, and San Antonio lands at No. 8.

Minneapolis ranks first among the cities with the happiest workers.

Here's how Houston fared in the four ranking categories:

  • 16.6 million unused vacation days per year.
  • 40.1 average hours worked per week.
  • Median annual pay of $32,251.
  • Happiness score of out of 50.83.

Dallas had 19.4 million unused vacation days per year, 40.5 average hours worked per week, median annual pay of $34,479, and a happiness score of 53.3 out of 100.

Meanwhile, San Antonio had 5.7 million unused vacation days per year, 39.2 average hours worked per week, median annual pay of $25,894, and a happiness score of 48.61.

Texas tops Lensa's list of the states with the unhappiest workers.

"While the Lone Star State had a decent happiness score of 52.56 out of 100, it scored poorly on each of the other factors, with Texans allowing an incredible 67.1 million earned vacation days go to waste over the course of a year," Lensa says.

In terms of general happiness, Houston shows up at No. 123 on WalletHub's most recent list of the happiest U.S. cities. Dallas takes the No. 104 spot, and San Antonio lands at No. 141. Fremont, California, grabs the No. 1 ranking.

Trending News